Quantcast

Latest NOV-002 Stories

2011-06-28 07:30:00

MADISON, Wis., June 28, 2011 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that on June 23, 2011, Judge Nathaniel M. Gorton allowed the defendants' motion to dismiss the putative federal securities fraud class action brought in the United States District Court for the District of Massachusetts in March 2010 entitled Boris Urman and Ramona McDonald v. Novelos Therapeutics, Inc....

2010-05-10 08:10:00

SOUTH SAN FRANCISCO, Calif., May 10 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that data from the Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial evaluating the efficacy and safety of picoplatin as a second-line treatment in small cell lung cancer (SCLC) has been accepted for an oral presentation during the American Society of Clinical Oncology (ASCO) 2010...

2009-09-08 10:15:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Lung Cancer Therapeutics http://www.reportlinker.com/p0131247/Lung-Cancer-Therapeutics.html This report analyzes the worldwide markets (Annual Revenues) for Lung Cancer Therapeutics in Millions of US$. The US market for Non-Small Cell Lung Cancer treatment is further analyzed by: Chemotherapy Drugs, and Targeted Drugs. The report provides separate comprehensive...

2008-11-04 09:00:30

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Harry S. Palmin, President and CEO of Novelos, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008. Mr. Palmin is scheduled to present at 11:10am EST in Kennedy I, 4th floor. The event will be held at the New York Palace Hotel, 455 Madison Avenue, New York, NY. A live...

2008-09-10 09:00:48

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Harry S. Palmin, President and CEO of Novelos, will present at Merriman Curhan Ford's 5th annual Investor Summit on September 15, 2008. Mr. Palmin is scheduled to present at 8am PDT (11am EDT) in Track 1 - California Room. Mr. Palmin will also participate in a panel discussion "What's Next on the Horizon in Biotech?" at 1:45pm...

2008-08-18 09:00:16

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it received $3 million from the sale of 4,615,384 shares of its common stock at $0.65 per share to two accredited investors. The shares of common stock were issued in a private placement transaction under Regulation D of the Securities Act of 1933 and have not been registered under the Securities Act of 1933, as amended, or any...

2008-08-11 09:01:40

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Harry S. Palmin, President and CEO of Novelos, will present at the Noble Financial 4th Annual Equity Conference on Monday, August 18, 2008. Mr. Palmin is scheduled to present at 11am PDT (2pm EDT) at the Interceptor Room. The event will be held at the Lowes Lake Las Vegas Resort, Nevada. A live webcast of Mr. Palmin's...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.